Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

709.05INR
31 Jul 2015
Change (% chg)

Rs-2.00 (-0.28%)
Prev Close
Rs711.05
Open
Rs719.90
Day's High
Rs724.00
Day's Low
Rs706.00
Volume
2,031,688
Avg. Vol
1,665,502
52-wk High
Rs752.85
52-wk Low
Rs430.00

CIPL.NS

Chart for CIPL.NS

About

Cipla Limited (Cipla) is an India-based global pharmaceutical company. The Company’s portfolio includes approximately 2000 products in 65 therapeutic categories with one quality standard globally. Cipla’s turnover in 2012/13 was approximately 1.5 billion USD. The Company’s research and development focus on developing products... (more)

Overall

Beta: 0.47
Market Cap(Mil.): Rs571,047.69
Shares Outstanding(Mil.): 803.10
Dividend: 2.00
Yield (%): 0.28

Financials

  CIPL.NS Industry Sector
P/E (TTM): 48.55 36.75 40.14
EPS (TTM): 14.64 -- --
ROI: 11.18 16.48 15.75
ROE: 11.33 17.28 16.79
Search Stocks

Sensex extends gains for second session

MUMBAI - The BSE Sensex and Nifty rose on Thursday, posting their second consecutive session of gains, backed by strong earnings of Bank of Baroda and Dr Reddy's Laboratories while continued optimism over the proposed national tax bill also helped.

30 Jul 2015

BUZZ-India's Cipla gains for second day; partner Sandoz gets approval for key generic

** Partner Sandoz got U.S. FDA approval for 180 days sole exclusivity for generic version of Pulmicort respule used in treatment of Asthma on July 28: Sandoz's website shows

30 Jul 2015

MEDIA-Samina Vaziralli to take India's Cipla legacy forward - Economic Times

- Note: Reuters has not verified this story and does not vouch for its accuracy

15 Jul 2015

INTERVIEW-India's Cipla expects to double respiratory drug sales by 2020

MUMBAI, June 17 - Indian generic drugmaker Cipla expects sales from its respiratory portfolio to more than double by 2020 and remains on track to launch its potentially lucrative inhaler in Britain, its chief executive said.

17 Jun 2015

India's Cipla expects to double respiratory drug sales by 2020

MUMBAI - Indian generic drugmaker Cipla expects sales from its respiratory portfolio to more than double by 2020 and remains on track to launch its potentially lucrative inhaler in Britain, its chief executive said.

17 Jun 2015

Interview - Cipla expects to double respiratory drug sales by 2020

MUMBAI - Generic drugmaker Cipla expects sales from its respiratory portfolio to more than double by 2020 and remains on track to launch its potentially lucrative inhaler in Britain, its chief executive said.

17 Jun 2015

INTERVIEW-India's Cipla expects to double respiratory drug sales by 2020

* Says plans to enter Latin America, Eastern Europe (Adds detail, fresh CEO comments)

17 Jun 2015

India's Cipla to sharpen focus on emerging markets in growth push

MUMBAI, June 17 - Cipla Ltd, India's fourth-largest drugmaker by sales, is planning to enter Latin America and Eastern Europe to tap into growing demand for generic drugs in emerging markets, Chief Executive Subhanu Saxena said.

17 Jun 2015

Lupin, Cipla bid for UCB's U.S. generic drugs portfolio - Bloomberg

MUMBAI - Generic drugmakers Lupin Ltd and Cipla Ltd are among the companies bidding for top Belgian drugmaker UCB SA's U.S. generic drugs business, Bloomberg reported on Monday, citing unnamed people with knowledge of the matter.

01 Jun 2015

India's Lupin, Cipla bid for UCB's US generic drugs portfolio - Bloomberg

MUMBAI, June 1 - Indian generic drugmakers Lupin Ltd and Cipla Ltd are among the companies bidding for top Belgian drugmaker UCB SA's U.S. generic drugs business, Bloomberg reported on Monday, citing unnamed people with knowledge of the matter.

01 Jun 2015

Earnings vs. Estimates

Search Stocks